Personal information

Keywords

AML, AI, ML

Activities

Collapse all

Works (24)

Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia – long-term follow-up with focus on younger patients

Blood Cancer Journal
2025-04-08 | Journal article
DOI: 10.1038/s41408-025-01274-0
Contributors: Christina Rautenberg; Jan Moritz Middeke; Christoph Röllig; Matthias Stelljes; Verena Gaidzik; Oliver Kriege; Mareike Verbeek; Katrin Koch; Julia Marie Unglaub; Felicitas Thol et al.
Source: check_circle
Crossref

UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome

Blood Cancer Journal
2023-05-26 | Journal article
DOI: 10.1038/s41408-023-00858-y
Contributors: Julia-Annabell Georgi; Sebastian Stasik; Jan-Niklas Eckardt; Sven Zukunft; Marita Hartwig; Christoph Röllig; Jan Moritz Middeke; Uta Oelschlägel; Utz Krug; Tim Sauer et al.
Source: check_circle
Crossref

Correction to: Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: results of a prospective observational study

Bone Marrow Transplantation
2022-01 | Journal article
DOI: 10.1038/s41409-021-01524-2
Contributors: Johannes Schetelig; Jennifer Hoek; Stephan Stilgenbauer; Jan Moritz Middeke; Niels Smedegaard Andersen; Christopher P. Fox; Stig Lenhoff; Liisa Volin; Avichai Shimoni; Wilfried Schroyens et al.
Source: check_circle
Crossref

Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears

Leukemia
2022-01 | Journal article
DOI: 10.1038/s41375-021-01408-w
Contributors: Jan-Niklas Eckardt; Jan Moritz Middeke; Sebastian Riechert; Tim Schmittmann; Anas Shekh Sulaiman; Michael Kramer; Katja Sockel; Frank Kroschinsky; Ulrich Schuler; Johannes Schetelig et al.
Source: check_circle
Crossref

Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study

Bone Marrow Transplantation
2021-03-16 | Journal article
DOI: 10.1038/s41409-020-01013-y
Contributors: Johannes Schetelig; Jennifer Hoek; Stephan Stilgenbauer; Jan Moritz Middeke; Niels Smedegaard Andersen; Christopher P. Fox; Stig Lenhoff; Liisa Volin; Avichai Shimoni; Wilfried Schroyens et al.
Source: check_circle
Crossref

Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology

Journal of Autoimmunity
2018-06 | Journal article
DOI: 10.1016/j.jaut.2018.02.006
Contributors: Stefanie Koristka; Alexandra Kegler; Ralf Bergmann; Claudia Arndt; Anja Feldmann; Susann Albert; Marc Cartellieri; Armin Ehninger; Gerhard Ehninger; Jan Moritz Middeke et al.
Source: check_circle
Crossref

Pilot Study on Mass Spectrometry–Based Analysis of the Proteome of CD34<sup>+</sup>CD123<sup>+</sup> Progenitor Cells for the Identification of Potential Targets for Immunotherapy in Acute Myeloid Leukemia

Proteomes
2018-02 | Journal article
DOI: 10.3390/proteomes6010011
Source: check_circle
Multidisciplinary Digital Publishing Institute
grade
Preferred source (of 2)‎

Karyotype complexity and prognosis in acute myeloid leukemia.

2016 | Journal article
DOI: 10.1038/bcj.2015.114
PMID: 26771812
PMC: PMC4742631
Contributors: Stölzel F; Mohr B; Kramer M; Oelschlägel U; Bochtler T; Berdel WE; Kaufmann M; Baldus CD; Schäfer-Eckart K; Stuhlmann R et al.
Source: Self-asserted source
Jan Moritz Middeke via Europe PubMed Central

TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation.

2016-03 | Journal article
DOI: 10.1111/bjh.13912
PMID: 26771088
Contributors: Middeke JM; Herold S; Rücker-Braun E; Berdel WE; Stelljes M; Kaufmann M; Schäfer-Eckart K; Baldus CD; Stuhlmann R; Ho AD et al.
Source: Self-asserted source
Jan Moritz Middeke via Europe PubMed Central

Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial.

2016-02 | Journal article
DOI: 10.1038/leu.2015.226
PMID: 26283567
Contributors: Middeke JM; Herbst R; Parmentier S; Bug G; Hänel M; Stuhler G; Schäfer-Eckart K; Rösler W; Klein S; Bethge W et al.
Source: Self-asserted source
Jan Moritz Middeke via Europe PubMed Central

Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation.

2016-01 | Journal article
DOI: 10.1038/bmt.2015.339
PMID: 26752141
Contributors: Link CS; Teipel R; Heidenreich F; Rücker-Braun E; Schmiedgen M; Reinhardt J; Oelschlägel U; von Bonin M; Middeke JM; Muetherig A et al.
Source: Self-asserted source
Jan Moritz Middeke via Europe PubMed Central

Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia.

2016-01 | Journal article
PMID: 26784000
Contributors: Österborg A; Udvardy M; Zaritskey A; Andersson PO; Grosicki S; Mazur G; Kaplan P; Steurer M; Schuh A; Montillo M et al.
Source: Self-asserted source
Jan Moritz Middeke via Europe PubMed Central

Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease.

2015-04 | Journal article
DOI: 10.1016/j.jcyt.2014.11.005
PMID: 25573333
Contributors: Theil A; Tuve S; Oelschlägel U; Maiwald A; Döhler D; Oßmann D; Zenkel A; Wilhelm C; Middeke JM; Shayegi N et al.
Source: Self-asserted source
Jan Moritz Middeke via Europe PubMed Central

Allogeneic stem cell transplantation for the treatment of refractory scleromyxedema

Translational Research
2015-02 | Journal article
DOI: 10.1016/j.trsl.2014.06.002
Source: check_circle
Crossref

Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.

2014-05 | Journal article
DOI: 10.1182/blood-2013-12-544957
PMID: 24652988
Contributors: Middeke JM; Fang M; Cornelissen JJ; Mohr B; Appelbaum FR; Stadler M; Sanz J; Baurmann H; Bug G; Schäfer-Eckart K et al.
Source: Self-asserted source
Jan Moritz Middeke via Europe PubMed Central

Use of rasburicase in a pregnant woman with acute lymphoblastic leukaemia and imminent tumour lysis syndrome.

2014-03 | Journal article
DOI: 10.1007/s00277-013-1836-8
PMID: 23820942
Contributors: Middeke JM; Bruck N; Parmentier S; Bornhäuser M; Schetelig J
Source: Self-asserted source
Jan Moritz Middeke via Europe PubMed Central

Early intervention with allogeneic hematopoietic cell transplantation during chemotherapy-induced aplasia in patients with high-risk acute myeloid leukemia.

2013-10 | Journal article
DOI: 10.1038/leu.2013.142
PMID: 23648670
Contributors: Stölzel F; Platzbecker U; Mohr B; Röllig C; Middeke JM; Thiede C; Füssel M; Hänel M; Schaich M; Ehninger G et al.
Source: Self-asserted source
Jan Moritz Middeke via Europe PubMed Central

Impact of allogeneic haematopoietic stem cell transplantation in patients with abnl(17p) acute myeloid leukaemia.

2013-04 | Journal article
DOI: 10.1111/bjh.12253
PMID: 23432431
Contributors: Mohr B; Schetelig J; Schäfer-Eckart K; Schmitz N; Hänel M; Rösler W; Frickhofen N; Link H; Neubauer A; Schuler U et al.
Source: Self-asserted source
Jan Moritz Middeke via Europe PubMed Central

Reconstitution of interleukin-17-producing T helper cells after allogeneic hematopoietic cell transplantation.

2013-03 | Journal article
DOI: 10.1016/j.bbmt.2012.11.018
PMID: 23207644
Contributors: Bahr F; Wehner R; Platzbecker U; Wermke M; Shayegi N; Middeke JM; Röllig C; Schetelig J; Ehninger G; Schmitz M et al.
Source: Self-asserted source
Jan Moritz Middeke via Europe PubMed Central

Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation.

2013-01 | Journal article
DOI: 10.1007/s00277-012-1524-0
PMID: 22820970
Contributors: Ordemann R; Stöhlmacher J; Beuthien-Baumann B; Platzek I; van den Hoff J; Kroschinsky F; Middeke JM; Platzbecker U; Zietz C; Bornhäuser M et al.
Source: Self-asserted source
Jan Moritz Middeke via Europe PubMed Central

MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation.

2012-12 | Journal article
DOI: 10.1158/1078-0432.CCR-12-1683
PMID: 22991415
Contributors: Wermke M; Schmidt A; Middeke JM; Sockel K; von Bonin M; Schönefeldt C; Mair S; Plodeck V; Laniado M; Weiss G et al.
Source: Self-asserted source
Jan Moritz Middeke via Europe PubMed Central

Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and -5/5q-.

2012-09 | Journal article
DOI: 10.1182/blood-2012-03-417972
PMID: 22855604
Contributors: Middeke JM; Beelen D; Stadler M; Göhring G; Schlegelberger B; Baurmann H; Bug G; Bellos F; Mohr B; Buchholz S et al.
Source: Self-asserted source
Jan Moritz Middeke via Europe PubMed Central

Reconstitution of 6-sulfo LacNAc dendritic cells after allogeneic stem-cell transplantation.

2012-06 | Journal article
DOI: 10.1097/TP.0b013e31824fd8b4
PMID: 22643330
Contributors: Mager K; Wehner R; Bahr F; Oelschlägel U; Platzbecker U; Wermke M; Shayegi N; Middeke JM; Radke J; Röllig C et al.
Source: Self-asserted source
Jan Moritz Middeke via Europe PubMed Central

Haploidentical bone marrow transplantation with post-grafting cyclophosphamide: multicenter experience with an alternative salvage strategy.

2011-05 | Journal article
DOI: 10.1038/leu.2011.11
PMID: 21311556
Contributors: Tuve S; Gayoso J; Scheid C; Radke J; Kiani A; Serrano D; Platzbecker U; Rodríguez-Macías G; Wermke M; Holtick U et al.
Source: Self-asserted source
Jan Moritz Middeke via Europe PubMed Central

Peer review (1 review for 1 publication/grant)

Review activity for Leukemia (1)
How many people are using ORCID?